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Summary
Genetic counselling may be offered to families with melanoma and to individuals with multiple
melanomas to better understand the genetic susceptibility of the disease, the influence of
environmental factors, the inheritance of the risk and behaviour that decreases the risk of dying
from melanoma including specific dermatological follow-up such as total body photography and
digital dermoscopy. Genetic testing may be offered to those individuals with more than a 10%
chance of being a carrier of a mutation. This risk varies according to the incidence of melanoma in
the country and sun behaviour. In countries with a low-medium incidence of melanoma, genetic
testing should be offered to families with two cases of melanoma or an individual with two
primary melanomas. In countries with a high incidence, families with three cases of melanoma,
with two melanomas and one pancreatic adenocarcinoma, or patients with three primary
melanomas may benefit from genetic testing.
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Genetic susceptibility to melanoma
The aetiology of melanoma is heterogeneous and complex. Genetic, phenotypical and
environmental factors are involved in melanoma susceptibility. Ultraviolet (UV) radiation
exposure has been identified as the principal environmental cause. UV radiation promotes
DNA damage through the formation of dimeric photoproducts, gene mutations, oxidative
stress, inflammation and immuno-suppression.
Physical traits, such as blonde or red hair, green or blue eyes, presence of freckles, multiple
(100 or more) melanocytic naevi (moles), and five or more atypical naevi, are also risk
factors (1). A prior diagnosis of melanoma is associated with an eight-fold increased risk of
a second primary melanoma (2).
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Many familial cancer syndromes are recognised by so-called high-risk features, including a
cluster of relatives within the patient’s family who have the same or similar cancers (more
than two family members with cancer over two or more generations), the development of
cancer at a young age, the presentation of more than one tumour or more than one tumour
within a specific group of tumours that are features of a syndrome (3)
In the case of melanoma, it is estimated that 5–10% of all cases occur in families (4). In
these families, the pattern of susceptibility is consistent with an autosomal dominant
inheritance with incomplete penetrance (5), thus relatives of these patients are at an
increased risk of developing melanoma. In families, the research has been directed at
identifying those genes implicated in melanoma susceptibility and to use this data to provide
genetic counselling to families with melanoma (6).
Two high penetrance genes have been implicated in melanoma susceptibility: CDKN2A and
CDK4. The tumour suppressor gene CDKN2A encodes two different proteins: the α
transcript encodes the p16 protein, that regulates G1-phase exit by inhibiting the CDK4-
mediated phosphorylation of the retinoblastoma protein (7, 8) The β transcript encodes the
alternative product p14ARF which acts via the p53 pathway to induce cell cycle arrest or
apoptosis (9, 10). Also, both P53 and p16INK4A have roles in responses to DNA damage
and cellular senescence (11, 12). CDK4 which is an oncogene, encodes one of the binding
partners of p16 (13). Only two mutations have been described to date and both are located in
the same codon, affecting the protein domain of interaction with p16 which results in
disabling the p16 protein from inhibiting the D1-cyclin-dependent kinase 4 mutant complex.
The functions of CDKN2A and CDK4 in melanoma development, however, are currently
incompletely understood. By definition these genes have a high penetrance and therefore
there are usually multiple cases of cancer in the affected family.
To date, the number of CDK4 mutant melanoma families is reduced compared to the
frequency of CDKN2A mutations in melanoma-prone families. Overall, 20% of melanoma
prone families have germinal CDKN2A mutations but this varies from 5% to 72%
depending on the selection criteria used and it is also highly variable across regions (14).
The likelihood of detecting a mutation increases with the number of affected members
detected, in some populations being 4% for two melanoma cases, 8% for three melanoma
cases and 38% for three or more melanoma cases (14, 15). On the other hand, the risk of
being a carrier for a melanoma patient with no family history of the disease is approximately
of 1%.
The multiple case family studies indicate that the life-time risk of melanoma (penetrance) in
CDKN2A mutation carriers is very high, ranging from 58% in Europe to 91% in Australia
by age 80 years. But the penetrance of CDKN2A mutations in the general population may
be much lower. It was calculated that the risk of melanoma in CDKN2A mutation carriers is
28% by age 80 in a population-based study (15).
In some families there appears to be a pre-disposition to a variety of different cancers. In a
study by the International Consortium GENOMEL, the presence of pancreatic cancer in a
family was strongly associated with the occurrence of a CDKN2A mutation (28% of
families with a CDKN2A mutation had pancreatic cancer versus 6% of families with no
mutation) (14). Nevertheless, in the majority of families with high penetrance melanoma
susceptibility genes the predisposition appears to be to melanoma only.
A controversial issue is the effect of common CDKN2A variants in melanoma susceptibility.
Multiples studies suggest that polymorphism p.A148T could be considered as a low
penetrance melanoma susceptibility allele in some populations (16, 17) or in multiple
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primary melanoma patients (18). However, such findings have not been found in other
studies (19, 20).
Two medium penetrance susceptibility genes have also been implicated in melanoma
susceptibility: MC1R and MITF. The melanocortin-1 receptor (MC1R) encodes the
melanocyte-stimulating hormone receptor and is involved in the pigmentation process (21).
MC1R is highly polymorphic in the Caucasian population. These variants have varying
effects on the receptor’s function, its ability to modify melanogenesis and thus, the
eumelanin/pheomelanin ratio (22, 23). Variants in the MC1R gene are strongly associated
with skin and hair pigmentation and also contribute to melanoma risk independent of these
phenotypical features (24). There are large studies which confer the red-hair associated
(RHC) subset of MC1R variants with increased melanoma risk. This risk varies from around
two -fold per RHC allele in the populations, to three-fold in melanoma families. The risk is
additive, carriers of two RHC alleles have a risk four-to six-fold higher than non-RHC
carriers. Moreover, coinheritance of variants in MC1R with CDKN2A mutations increases
the penetrance of melanoma in such mutation positive families (25, 26). Interestingly, the
presence of two MC1R RHC variants in early melanomas was also associated with the
presence of less dermoscopic structures and colours, thus being more difficult to diagnose.
However, it is not clear how MC1R variants can be incorporated into clinical practice
without taking into account their phenotypical effect.
Microphthalmia-associated transcription factor (MITF) is a master regulator gene of
melanocyte development and differentiation and is also associated with melanoma
development and progression (27). Recently it has been implicated in melanoma
susceptibility. Mutation p.E318K (rs149617956) has been implicated both in familial and
sporadic melanoma susceptibility (Odds Ratio -OR- 2.33), and in melanoma and/or renal
cell carcinoma patients (28, 29). This variant was also associated with increased naevus
count and non-blue eye colour (28).
The impact of the inheritance of low-medium penetrance genes in melanoma predisposition
is weak, with maybe only one or occasionally two cases in a family. Co-inheritance of more
than one low-medium penetrance gene may result in more marked clustering of melanoma
in some families. As UV radiation is also implicated in melanoma susceptibility, families
carrying these low-medium penetrance genes may have more melanoma cases if they live in
areas of the world where the UV radiation is high.
Genetic counselling/assessment in melanoma
Genetic assessment in familial melanoma is a non directed process offered to families to
better understand the meaning of the disease, the meaning of genetic susceptibility, the
patterns of inheritance, the option of genetic testing, the understanding of all the possible
results and the primary and secondary prevention of melanoma as well. The process includes
melanoma risk assessment, genetic testing, informed consent, disclosure of test results and
psychosocial assessment as in other cancer genetic counselling or assessment (30).
One of the most important benefits of genetic assessment in melanoma is the identification
of individuals with increased risk of developing this cancer. It has to distinguish between
those with a high risk (high penetrance melanoma genes/families), those with a moderately
increased risk (multifactor aetiology or low penetrance alleles) and those with an average
risk (30). This information can also be used to assess other at-risk individuals in the family.
Patients with a personal and/or family history suggestive of an increased melanoma risk
should be directed to a melanoma genetic assessment unit. Genetic counselling often implies
genetic testing. Nevertheless, all patients can benefit from genetic counselling, even if they
are not candidates for genetic testing. Genetic counselling in cancer has been accepted and is
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used in clinical practice for breast, ovarian, colorectal and medullary thyroid and diffuse
gastric cancers. Its utility in patient screening and management is well documented (30).
Genetic testing for melanoma has been available since the CDKN2A gene (the major gene
implicated in melanoma predisposition) was identified in 1994 (31, 32). Nevertheless its use
in clinical practice has been controversial due to the variation in the estimates of CDKN2A
mutation penetrance (28–91%) depending on how the study is designed, the ethnic
background, UV exposure and co-inheritance of low-medium predisposing gene mutations
(such as MC1R gene variants) (33). Moreover, when genetic testing is performed, it is also
difficult to assess patients because individuals negative for the mutation segregating in the
family are still at increased risk of melanoma. Thus, some people would consider family
history of melanoma alone as good a method for assessment as genetic testing.
Genetic testing for melanoma predisposing mutations (in CDK4 and CDKN2A, including its
alternative transcript) could be used in a clinical setting if attention is paid to the selection of
patients, and a valid test interpretation and genetic counselling is given. People should be
aware of the difficulty of interpreting test results and the potentially limited impact on
clinical management. Only individuals with at least a 10% pre-test chance of carrying a
mutation should be considered as candidates for genetic testing. These individuals should
belong to melanoma families or melanoma/related cancer families (sarcoma, early onset
breast cancer, brain tumours or pancreatic cancer), and/or have multiple primary
melanomas. Patients with an early age at onset or with multiple or atypical naevi do not
fulfil criteria for genetic testing, unless they also have a family history of melanoma (34, 35)
(Table 1). Leachman et al (36) described a very useful rule to select patients for genetic
testing in melanoma, the rule of two for low melanoma incidence countries, such as
Southern Europe, the rule of three for medium-high melanoma incidence countries, such as
the USA and Northern Europe (Table 2). Also a rule of four for very high melanoma
incidence countries, such as Australia, may be suggested. They use different criteria
according to the incidence of melanoma and prevalence of mutations in each region. In the
United States (medium-high incidence of melanoma) we should consider for genetic
assessment individuals with three or more primary invasive melanomas and families with at
least one invasive melanoma and two more cases of melanoma and/or pancreatic cancer
among first- or second-degree relatives on the same side of the family. In Southern Europe
we should consider for genetic testing individuals with two (synchronous or metachronous)
primary melanomas and/or families with at least one invasive melanoma and one or more
other diagnoses of melanoma and/or pancreatic cancers among first- or second-degree
relatives on the same side of the family
When genetic testing detects a melanoma predisposing mutation in a family, cascade
screening of at risk individuals is recommended. Carriers of a mutation are at high risk of
developing multiple melanomas and also, in some families, of pancreatic cancer in their
lifetime (37, 38) (Figure 1). Increased skin-cancer screening and surveillance by physicians
and self skin examination results in earlier detection of thinner melanomas (39, 40). As
regards pancreatic cancer, patients should be aware of the current lack of effective screening
guidelines (41).
In families where no CDKN2A mutation is identified, it should be stressed that the family is
still at increased risk of melanoma on the basis of the family history. No further information
on cancer risk is obtained, so these families should be managed according to family history.
Genetic counselling aims to help patients and families. Genetic counsellors should inform
patients about the genetic risk factors for melanoma (Table 3) and other cancers, the
indications for genetic testing, the chance of detecting a mutation, the possible reports
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(positive, negative or inconclusive), the possible implications for other family members,
give psychological assessment, and also offer recommendations for cancer screening and
UV protection and how these might change with testing. Although mutations can be
detected in these patients, families and patients negative for a familial mutation still have up
to a two-fold greater risk of developing melanoma than that of the general population, due to
other melanoma susceptibility genes and environmental factors shared between families (42,
43). Identification of the missing attributable risk in those individuals with a familial
aggregation to melanoma is essential to improve genetic counselling in these families. The
high-throughput molecular methodologies such as SNP-array or more recently next
generation sequencing constitute powerful tools to identify new high or medium
susceptibility genes. Recently, a new approach to predisposition gene identification has
identified new chromosomic regions linked to melanoma risk in pedigrees (44, 45).
Early detection of melanoma is crucial for survival. Thin melanomas have a good outcome
while advanced melanomas have a poor prognosis. Genetic counselling and testing can
identify mutation carriers in high-risk families. These individuals can benefit from the
advantages of prevention and early detection practices (33, 40, 46). In 2011, Salerni et al
(46) demonstrated again that the inclusion of patients who are at high risk for melanoma in
follow-up programs allows the detection of melanomas at early stages, with good prognosis,
even in the absence of clinical and dermoscopic features of melanoma. In a second study,
reporting the experience of more than 10 years of follow up of high risk patients, Salerni et
al (40) reported that digital follow up with specific dermatologic techniques including total
body photography and digital dermoscopy permitted early detection of melanomas with a
low rate of excisions. They also reported that long-term follow-up is required to allow the
detection of slow-growing melanomas. Based on this 10-year experience, melanomas can be
diagnosed at any time, suggesting that in a population at high risk for melanoma, follow up
should be maintained over time.
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Pedigree of a CDKN2A mutation carrier family with 3 melanoma cases
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Table 1
Features associated with genetic testing for melanoma predisposition
Feature
Family history of melanoma
Depending on incidence of melanoma in specific population may be two or three cases of melanoma on the same side of the family
Multiple Primary Melanoma patients
The likelihood of mutation detection increases with the number of primaries in an individual
Pancreatic cancer
presence of pancreatic cancer in a melanoma family
Age of MM <40 y.
No genetic testing recommended as an isolate feature
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Table 2
Criteria for genetic testing according to melanoma incidence.
Low melanoma incidence area/population
• Two primary melanomas in an individual, or
• Two cases of melanoma among first- or second-degree relatives, or
• One case of melanoma and one case of pancreatic cancer in first- or second-degree relatives.
Moderate to high melanoma incidence area/population
• Three primary melanomas in an individual, or
• Three cases of melanoma in first- or second-degree relatives, or
• Two cases of melanoma and one pancreatic cancer in first- or second-degree relatives, or
• One case of melanoma and two of pancreatic cancer in first- or second-degree relatives.
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Table 3
Risk Factors for the Development of Melanoma
Factor Approximate Relative Risk
Member of melanoma-prone family* Up to 35–70
Previous primary melanoma 8.5
Family history of melanoma† 2–3




History of blistering sunburn 2–3
Multiple moles and atypical moles 2–12.7
*
Multiple affected relatives on the same side of the family.
†
One or more affected first-degree relatives.
Data from Kefford et al (1999)
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